Neoprobe to Present at Rodman & Renshaw Healthcare Conference

DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that its President and Chief Executive Officer, David Bupp, will present on Monday, May 19, 2008 at 2:50PM local time (8:50AM ET), in the Zephyr Salon, during the Rodman & Renshaw 5^th Annual Global Healthcare Conference to be held at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Mr. Bupp’s presentation will provide an overview of the company’s technology, business strategy and current developments.

Interested parties can access a live or an archived internet broadcast of the presentation at:

http://wsw.com/webcast/rrshq13/neop.ob

The presentation will be archived for 30 days.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000^® line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix^® line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek^® and RIGScan^® CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions.www.neoprobe.com